News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
642,583 Results
Type
Article (40506)
Company Profile (155)
Press Release (601922)
Multimedia
Podcasts (56)
Webinars (10)
Section
Business (175429)
Career Advice (2799)
Deals (35023)
Drug Delivery (97)
Drug Development (73469)
Employer Resources (160)
FDA (15837)
Job Trends (14858)
News (307106)
Policy (29832)
Tag
Academia (2720)
Academic (1)
Accelerated approval (10)
Adcomms (25)
Allergies (105)
Alliances (44274)
ALS (116)
Alzheimer's disease (1532)
Antibody-drug conjugate (ADC) (152)
Approvals (15862)
Artificial intelligence (353)
Autoimmune disease (38)
Automation (20)
Bankruptcy (301)
Best Places to Work (12171)
BIOSECURE Act (18)
Biosimilars (121)
Biotechnology (107)
Bladder cancer (98)
Brain cancer (37)
Breast cancer (388)
Cancer (3009)
Cardiovascular disease (223)
Career advice (2329)
Career pathing (33)
CAR-T (195)
CDC (30)
Cell therapy (545)
Cervical cancer (22)
Clinical research (60957)
Collaboration (1091)
Company closure (2)
Compensation (716)
Complete response letters (25)
COVID-19 (2558)
CRISPR (64)
C-suite (376)
Cystic fibrosis (120)
Data (3222)
Decentralized trials (1)
Denatured (13)
Depression (65)
Diabetes (348)
Diagnostics (6731)
Digital health (25)
Diversity (7)
Diversity, equity & inclusion (40)
Drug discovery (162)
Drug pricing (114)
Drug shortages (24)
Duchenne muscular dystrophy (140)
Earnings (70295)
Editorial (44)
Employer branding (21)
Employer resources (142)
Events (104548)
Executive appointments (910)
FDA (17660)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (976)
Gene editing (141)
Generative AI (31)
Gene therapy (406)
GLP-1 (747)
Government (4233)
Grass and pollen (6)
Guidances (216)
Healthcare (20005)
HIV (42)
Huntington's disease (28)
IgA nephropathy (40)
Immunology and inflammation (152)
Immuno-oncology (10)
Indications (42)
Infectious disease (2741)
Inflammatory bowel disease (160)
Inflation Reduction Act (9)
Influenza (72)
Intellectual property (130)
Interviews (551)
IPO (16392)
IRA (42)
Job creations (3096)
Job search strategy (1922)
Kidney cancer (15)
Labor market (43)
Layoffs (490)
Leadership (26)
Legal (6752)
Liver cancer (72)
Longevity (11)
Lung cancer (408)
Lymphoma (210)
Machine learning (12)
Management (60)
Manufacturing (427)
MASH (97)
Medical device (14201)
Medtech (14207)
Mergers & acquisitions (19487)
Metabolic disorders (818)
Multiple sclerosis (99)
NASH (13)
Neurodegenerative disease (147)
Neuropsychiatric disorders (39)
Neuroscience (2264)
NextGen: Class of 2025 (6847)
Non-profit (4868)
Now hiring (40)
Obesity (388)
Opinion (250)
Ovarian cancer (106)
Pain (123)
Pancreatic cancer (127)
Parkinson's disease (198)
Partnered (21)
Patents (325)
Patient recruitment (186)
Peanut (53)
People (52754)
Pharmaceutical (43)
Pharmacy benefit managers (20)
Phase I (18982)
Phase II (27000)
Phase III (20206)
Pipeline (1727)
Policy (191)
Postmarket research (2085)
Preclinical (7818)
Press Release (62)
Prostate cancer (147)
Psychedelics (36)
Radiopharmaceuticals (271)
Rare diseases (497)
Real estate (5063)
Recruiting (64)
Regulatory (21442)
Reports (33)
Research institute (2480)
Resumes & cover letters (456)
Rett syndrome (9)
RNA editing (9)
RSV (54)
Schizophrenia (98)
Series A (162)
Series B (115)
Service/supplier (7)
Sickle cell disease (69)
Special edition (16)
Spinal muscular atrophy (148)
Sponsored (28)
Startups (3213)
State (2)
Stomach cancer (8)
Supply chain (77)
Tariffs (56)
The Weekly (42)
Vaccines (765)
Venture capital (49)
Weight loss (224)
Women's health (39)
Worklife (19)
Date
Today (76)
Last 7 days (538)
Last 30 days (1861)
Last 365 days (32518)
2025 (19009)
2024 (36484)
2023 (41508)
2022 (52611)
2021 (57309)
2020 (55873)
2019 (49126)
2018 (37035)
2017 (32623)
2016 (30983)
2015 (36163)
2014 (25447)
2013 (20107)
2012 (21567)
2011 (22414)
2010 (19620)
Location
Africa (799)
Alabama (69)
Alaska (7)
Arizona (181)
Arkansas (12)
Asia (37860)
Australia (6656)
California (7799)
Canada (2460)
China (701)
Colorado (330)
Connecticut (342)
Delaware (204)
Europe (87393)
Florida (1187)
Georgia (271)
Hawaii (2)
Idaho (61)
Illinois (676)
India (26)
Indiana (382)
Iowa (17)
Japan (241)
Kansas (108)
Kentucky (32)
Louisiana (16)
Maine (73)
Maryland (1062)
Massachusetts (5956)
Michigan (273)
Minnesota (476)
Mississippi (3)
Missouri (104)
Montana (31)
Nebraska (26)
Nevada (86)
New Hampshire (72)
New Jersey (2192)
New Mexico (30)
New York (2182)
North Carolina (1170)
North Dakota (10)
Northern California (3460)
Ohio (252)
Oklahoma (16)
Oregon (36)
Pennsylvania (1690)
Puerto Rico (17)
Rhode Island (38)
South America (1135)
South Carolina (35)
South Dakota (1)
Southern California (2955)
Tennessee (129)
Texas (1190)
United States (29168)
Utah (233)
Virginia (203)
Washington D.C. (70)
Washington State (669)
West Virginia (3)
Wisconsin (76)
642,583 Results for "viatris acquired by meda ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
July 18, 2025
·
5 min read
Press Releases
Viatris Announces Quarterly Dividend
May 7, 2025
·
3 min read
Press Releases
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
August 1, 2025
·
5 min read
Press Releases
Viatris to Participate in Upcoming June 2025 Investor Conferences
May 22, 2025
·
1 min read
Press Releases
Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025
June 12, 2025
·
1 min read
Press Releases
Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada
May 28, 2025
·
4 min read
Press Releases
Viatris to Present at the BofA Securities 2025 Healthcare Conference
April 25, 2025
·
1 min read
Press Releases
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
May 8, 2025
·
41 min read
Press Releases
Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
April 14, 2025
·
4 min read
Press Releases
Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
June 26, 2025
·
7 min read
1 of 64,259
Next
